@article {7836,
	title = {Treatment of early uterine sarcomas: Disentangling adjuvant modalities},
	journal = {World Journal of Surgical Oncology},
	volume = {7},
	year = {2009},
	note = {Cited By :24Export Date: 21 February 2017},
	month = {2009},
	pages = {38},
	abstract = {Uterine sarcomas are a rare group of neoplasms with aggressive clinical course and poor prognosis. They are classified into four main histological subtypes in order of decreasing incidence: carcinosarcomas, leiomyosarcomas, endometrial stromal sarcomas and "other" sarcomas. The pathological subtype demands a tailored approach. Surgical resection is regarded as the mainstay of treatment. Total abdominal hysterectomy and bilateral salpingo-oophorectomy represents the standard treatment of uterine sarcomas. Pelvic and para-aortic lymph node dissection in carcinosarcomas is recommended, given their high incidence of lymph node metastases, and may have a role in endometrial stromal sarcomas. Adjuvant radiation therapy has historically been of little survival value, but it appears to improve local control and may delay recurrence. Regarding adjuvant chemotherapy, there is little evidence in the literature supporting its use except for carcinosarcomas. However, more trials are needed to address these issues, especially, their sequential application. Patients with uterine sarcomas should be referred to large academic centers for participation in clinical trials. {\textcopyright} 2009 Zagouri et al; licensee BioMed Central Ltd.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-65449171696\&doi=10.1186\%2f1477-7819-7-38\&partnerID=40\&md5=8dc4befc899c9616cd63853f2d730566},
	author = {Zagouri, F. and Dimopoulos, A.-M. and Fotiou, S. and Kouloulias, V. and Papadimitriou, C.A.}
}
